TerminatedInterventionalPhase 2Last updated Dec 3, 2025

Hydroxychloroquine (HCQ) in Pediatric Interstitial Lung Disease (ILD)

Hydroxychloroquine in Pediatric ILD: START Randomized Controlled in Parallel-group, Then Switch Placebo to Active Drug, and STOP Randomized Controlled in Parallel-Group to Evaluate the Efficacy and Safety of Hydroxychloroquine (HCQ)

Overview

ClinicalTrials.gov ID: NCT02615938
Lead Sponsor: Matthias GrieseOTHER
Brief Summary: This is an exploratory Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multinational study investigating the initiation or withdrawal of hydroxychloroquine in subjects with chILD.
Study Type: Interventional

Status

Overall Status: Terminated
Start Date: Aug 21, 2015Actual
Primary Completion Date: Jun 27, 2019Actual
Completion Date: Sep 9, 2020Actual

Study Record Dates

First Submitted: Nov 8, 2015
First Submitted that Met QC Criteria: Nov 24, 2015
First Posted: Nov 26, 2015Estimated
Last Update Submitted that Met QC Criteria: Nov 18, 2025
Last Update Posted: Dec 3, 2025Actual
Last Verified: Nov 2025

NCT04532346Recruiting

Hydroxychloroquine in Children's Interstitial Lung Diseases With Genetic Causes

NCT03822780Completed

Hydroxychloroquin (HCQ) in chILD of Genetic Defect

NCT04461353Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers

NCT04382625Withdrawn

Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial

NCT05799378Recruiting

Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

NCT04345692Terminated

A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients